| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Combination therapy is one method of overcoming the global challenge of drug-resistant Plasmodium falciparum malaria. We conducted a hospital-based 28-day in vivo test comparing chloroquine/doxycycline to chloroquine or doxycycline alone for treating P. falciparum and Plasmodium vivax malaria in Irian Jaya, Indonesia. Eighty-nine patients with uncomplicated falciparum malaria were randomized to standard dose chloroquine (n = 30), doxycycline (100 mg every 12 hours [7 days], n = 20), or chloroquine with doxycycline (n = 39); corresponding numbers for vivax malaria (n = 63) were 23, 16, 24. Endpoints were parasite sensitivity (S) or resistance (RI/RII/RIII). Of the 105 evaluable patients, chloroquine/doxycycline cured (S) 20/22 (90.9% [95% CI 78.9-100%]) patients with P. falciparum malaria; 2/22 (9.1% [0-21%]) were RIII resistant. Doxycycline cured 11/17 (64.7% [42.0-87.4%]) patients, and chloroquine 4/20 (20% [2.5-37.5%]). Against P. vivax, chloroquine/doxycycline cured (S) 12/17 (70.6% [48.9-92.2%]) patients, doxycycline 4/12 (33.3% [6.6-59.9%]), and chloroquine 5/17 (29.4% [7.7-51.1%]). Chloroquine/doxycycline was effective against P. falciparum but only modestly effective against P. vivax. These findings support the use of chloroquine/doxycycline as an inexpensive alternative to mefloquine for treating chloroquine-resistant P. falciparum but not chloroquine-resistant P. vivax in this setting.
This article has been cited by other articles:
|
|
 |
|
  I. Sutanto, S. Suprijanto, Nurhayati, P. Manoempil, and J. K. Baird Resistance to Chloroquine by Plasmodium vivax at Alor in the Lesser Sundas Archipelago in Eastern Indonesia Am J Trop Med Hyg, August 1, 2009; 81(2): 338 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Baird Resistance to Therapies for Infection by Plasmodium vivax Clin. Microbiol. Rev., July 1, 2009; 22(3): 508 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. Dahl and P. J. Rosenthal Multiple Antibiotics Exert Delayed Effects against the Plasmodium falciparum Apicoplast Antimicrob. Agents Chemother., October 1, 2007; 51(10): 3485 - 3490. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. N. Newton, J.-F. Chaulet, A. Brockman, W. Chierakul, A. Dondorp, R. Ruangveerayuth, S. Looareesuwan, C. Mounier, and N. J. White Pharmacokinetics of Oral Doxycycline during Combination Treatment of Severe Falciparum Malaria Antimicrob. Agents Chemother., April 1, 2005; 49(4): 1622 - 1625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Baird Chloroquine Resistance in Plasmodium vivax Antimicrob. Agents Chemother., November 1, 2004; 48(11): 4075 - 4083. [Full Text] [PDF]
|
|
|
|
|
|
I. W. SUMAWINATA, BERNADETA, B. LEKSANA, A. SUTAMIHARDJA, PURNOMO, B. SUBIANTO, SEKARTUTI, D. J. FRYAUFF, and J. K. BAIRD VERY HIGH RISK OF THERAPEUTIC FAILURE WITH CHLOROQUINE FOR UNCOMPLICATED PLASMODIUM FALCIPARUM AND P. VIVAX MALARIA IN INDONESIAN PAPUA Am J Trop Med Hyg, April 1, 2003; 68(4): 416 - 420. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Hastings and C. H. Sibley Pyrimethamine and WR99210 exert opposing selection on dihydrofolate reductase from Plasmodium vivax PNAS, October 1, 2002; 99(20): 13137 - 13141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ohrt, G. D. Willingmyre, P. Lee, C. Knirsch, and W. Milhous Assessment of Azithromycin in Combination with Other Antimalarial Drugs against Plasmodium falciparum In Vitro Antimicrob. Agents Chemother., August 1, 2002; 46(8): 2518 - 2524. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
